Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MLTX vs WVE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MLTX Captures Overall Composite Edge (38.3 SELL vs 41.5 SELL), While WVE Leads 3–2 on Growth & Valuation Pillars

MLTX Overall Winner 6-Pillar Tally: MLTX 2 – 3 WVE (1 Tie) Matrix Metrics: MLTX 4 – 4 WVE

As of Nov 16, 2026, MoonLake Immunotherapeutics Class A (MLTX) captures the overall head-to-head institutional edge over Wave Life Sciences Ltd. (WVE) on higher Unified Composite conviction (38.3/100 SELL vs. 41.5/100 SELL) after splitting the core matrix 4–4 (led by Profitability & Quality, Options & Positioning), while WVE wins 3–2 across the 6-pillar growth and valuation breakdown. MLTX trades at $11.85 (N/M Forward P/E, 0.0% operating margin) versus WVE at $2.89 (N/M Forward P/E, -320.9% operating margin).

  • Composite vs. Pillar Nuance: While WVE currently prints a higher short-term Unified Composite Score (41.5/100 SELL vs. MLTX 38.3/100 SELL), MLTX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -320.9% operating margin) and revenue trajectory (+0.0% vs. +73.0% YoY).
  • Defensive Composite Rating Caution: Although MLTX compares more favorably head-to-head, both MLTX (38.3/100 SELL) and WVE (41.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: MLTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5); meanwhile WVE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MLTX vs WVE
MLTX NASDAQ Head-to-Head Winner
MoonLake Immunotherapeutics Class A Ordinary Shares
Pharmaceutical Preparations
$11.85
-5.2% 1D
Market Cap $1.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.61β · 90% Vol
Unified Composite Score
38.3 / 100 SELL
Tech 32.0 Fund 44.0 Flow 75.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -11.8%) with fading momentum, RSI 50
RSI-14: 49.5 · SMA20: $11.93 · SMA50: $11.82
WVE NASDAQ
Wave Life Sciences Ltd. Ordinary Shares
Pharmaceutical Preparations
$2.89
-7.82% 1D
Market Cap $621.3M
TTM Revenue $71M
Forward P/E N/M
Beta / 30D Vol 1.94β · 76% Vol
Unified Composite Score
41.5 / 100 SELL
Tech 21.0 Fund 46.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.2%), weak momentum, RSI 32
RSI-14: 32.1 · SMA20: $3.38 · SMA50: $3.69

6-Pillar Scorecard Institutional Category Breakdown (MLTX 2 – 3 WVE)

Columns: Metric · MLTX · WVE
1. Valuation Multiples WVE
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 6.6x
2. Growth & Scale WVE
Revenue Growth (YoY) +0.0% +73.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $71M
Market Cap $1.1B $621.3M
3. Profitability & Quality MLTX
Gross Margin N/A N/A
Operating Margin 0.0% -320.9%
Net Profit Margin 0.0% -296.9%
Return on Equity (ROE) -81.5% -78.8%
4. Balance Sheet & Cash Flow WVE
Cash Generation (TTM) -$244M -$208M
Cash Flow Margin N/A N/A
Net Cash / Leverage $278M Net Cash $154M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MLTX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 111.8% (7th %ile) 605.7% (62nd %ile)
Put/Call OI Skew N/A 0.31x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MLTX (4) vs WVE (4)
Institutional Metric MLTX WVE Criterion Row Edge
Market Capitalization
Scale
$1.1B $621.3M Larger Scale MLTX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +73.0% Higher Growth WVE
Operating Margin (TTM)
Profitability
0.0% -320.9% Higher Margin MLTX
Net Profit Margin
Profitability
0.0% -296.9% Higher Margin MLTX
Return on Equity (ROE)
Capital Efficiency
-81.5% -78.8% Higher ROE WVE
52-Week Range Position
Momentum
17% ($9–$23) 0% ($3–$21) Stronger Trend MLTX
Beta / 30D Volatility
Risk Regime
1.61β · 90% Vol 1.94β · 76% Vol Lower Realized Risk WVE
Unified Institutional Score
Composite Signal
38.3 / 100 (SELL) 41.5 / 100 (SELL) Higher Composite WVE
Trailing 12M Revenue (USD)
Operating Scale
N/A $71M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 6.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$244M ($278M Net Cash) -$208M ($154M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MLTX +31.9 pp
MLTX: +24.08% · WVE: -7.82%
3M Horizon MLTX +17.98 pp
MLTX: -27.48% · WVE: -45.46%
6M Horizon MLTX +27.0 pp
MLTX: -27.92% · WVE: -54.92%
1Y Horizon MLTX +51.1 pp
MLTX: -5.65% · WVE: -56.75%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MLTX vs WVE. Trailing 12-month operating profitability (MLTX 0.0% vs WVE -320.9%) and valuation multiples (MLTX N/M vs WVE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MLTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-81.5% · N/M
WVE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$71M
Gross MarginN/A
Op. Margin-320.9%
ROE / Fwd P/E-78.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MLTX BREAKDOWN
103d in phase · OBV ACCUMULATION
Current IV 111.8%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact MLTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
WVE BREAKDOWN
149d in phase · OBV NEUTRAL
Current IV 605.7%
IV Percentile 62nd %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact WVE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MLTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
WVE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $621.3M market capitalization and -320.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MLTX vs WVE Key Questions & Quantitative Answers

As of Nov 16, 2026, MoonLake Immunotherapeutics Class A (MLTX) captures the overall head-to-head institutional edge over Wave Life Sciences Ltd. (WVE) on higher Unified Composite conviction (38.3/100 SELL vs. 41.5/100 SELL) after splitting the core matrix 4–4 (led by Profitability & Quality, Options & Positioning), while WVE wins 3–2 across the 6-pillar growth and valuation breakdown. MLTX trades at $11.85 (N/M Forward P/E, 0.0% operating margin) versus WVE at $2.89 (N/M Forward P/E, -320.9% operating margin). Composite vs. Pillar Nuance: While WVE currently prints a higher short-term Unified Composite Score (41.5/100 SELL vs. MLTX 38.3/100 SELL), MLTX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -320.9% operating margin) and revenue trajectory (+0.0% vs. +73.0% YoY). Defensive Composite Rating Caution: Although MLTX compares more favorably head-to-head, both MLTX (38.3/100 SELL) and WVE (41.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MLTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5); meanwhile WVE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

WVE leads the Growth & Scale pillar: MLTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with WVE at +73.0% YoY revenue growth and +0.0% YoY earnings growth on $71M TTM revenue (N/A gross margin, -320.9% operating margin). On trailing 12-month operating scale, MLTX generates N/A in USD-normalized revenue versus $71M for WVE. In operating R&D and SG&A reinvestment, MLTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for WVE.

WVE screens cheaper on headline valuation multiples. MLTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas WVE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MLTX (-81.5% ROE) versus WVE (-78.8% ROE) capital efficiency.

In options market volatility and institutional positioning, MLTX carries 111.8% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.61β · 90% Vol realized risk). By comparison, WVE carries 605.7% implied volatility (62nd %ile, Elevated (60th–80th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.94β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.